Rigel entered into an exclusive license and supply agreement with Grifols, S.A. (Grifols) in January 2019, to commercialize fostamatinib disodium hexahydrate (fostamatinib) in all potential indications in Europe and Turkey.

In January 2020, Rigel received approval of its marketing authorization application (MAA) for fostamatinib for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments. The product is marketed in Europe under the brand name TAVLESSE (fostamatinib) and is the first and only spleen tyrosine kinase (SYK) inhibitor approved in Europe for this indication.

Rigel received an upfront cash payment, and is eligible for regulatory and commercial milestone payments, as well as tiered royalty payments on any future net sales of any products emerging from the collaboration.

European Commercial Launch

  • In July 2020, TAVLESSE was launched in Germany and the United Kingdom
  • A phased rollout of TAVLESSE is planned for the remaining European markets
  • In November 2020, Grifols exercised its option to expand its territory to include the Middle East, North Africa, Russia and CIS